Cambridge, UK; May 19, 2020. Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases, with a focus on gastroenterology, is pleased to support World IBD Day 2020 (worldibdday.org).

It is recognized that there is a need for new effective, convenient, safe and well-tolerated therapies for the treatment of Inflammatory Bowel Disease (IBD).

In November 2019, Prof. William Sandborn, University of California San Diego, presented his opinions on current treatment options at the United European Gastroenterology Week (UEGW) congress. He summarized that: “None of [the existing drugs] provide transformative efficacy, and novel drugs are needed.”

Atlantic Healthcare believes alicaforsen can address these needs and provide a step change in therapy for patients.

Furthermore, the global Covid-19 pandemic has heightened the awareness around the use of immuno-suppressive therapies and the increased potential of infections and other complications arising in immuno-suppressed patients1.

Atlantic Healthcare is developing alicaforsen using various topical delivery formulations, for the benefit of multiple patient groups with moderate to severe IBD.

Atlantic Healthcare’s lead program, an enema formulation for ulcerative colitis, is being prepared for a Phase 3 study. The Company is also developing separate oral tablet formulations, entering Phase 2b, for the treatment of ulcerative colitis and Crohn’s disease.

About Atlantic Healthcare

Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), is a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases, with a focus on gastroenterology.

The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug in development for ulcerative colitis and Crohn’s disease. In 2019, it also acquired the global rights to renzapride, which has the potential to address the unmet needs of multiple orphan disease patient groups suffering gastrointestinal motility disorders.

In due course Atlantic Healthcare intends to commercialize its products in Europe and the U.S. using a specialist sales team targeting healthcare professionals based in hospitals and specialist care centers. The Company plans to partner with established pharmaceutical companies to commercialize its products in the rest of the world.

The Company is led by an experienced international Board and Leadership Team, with deep roots and a proven track record in the pharmaceutical industry.

References:
1.https://www.ncbi.nlm.nih.gov/pubmed/27598743

For more information please contact:

 

Atlantic Healthcare

Toby Wilson Waterworth (CEO)

James Hansord (Director of Finance)

+44 1799 512 055

 

Adam Michael (Head of Communications)

+44 1799 512 055

+44 777 588 1813

adam.michael@atlantichc.com